periplocin: isolated from Periploca calophylla
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Periploca | genus | A plant genus of the family Apocynaceae. It is a source of periplocosides (pregnane steroid glycosides).[MeSH] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
Periploca calophylla | species | [no description available] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 14463159 |
MeSH ID | M0487436 |
Synonym |
---|
glucoperiplocymarin |
periplocin |
periplogenin + d-cymarose + d-glucose [german] |
periplocoside |
card-20(22)-enolide, 3-((2,6-dideoxy-4-o-beta-d-glucopyranosyl-3-o-methyl-beta-d-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-, (3-beta,5-beta)- |
brn 0075742 |
S9181 |
periplogenin + d-cymarose + d-glucose |
199x940o3k , |
unii-199x940o3k |
4-18-00-02439 (beilstein handbook reference) |
13137-64-9 |
AC-34379 |
card-20(22)-enolide, 3-((2,6-dideoxy-4-o-.beta.-d-glucopyranosyl-3-o-methyl-.beta.-d-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-, (3.beta.,5.beta.)- |
periplocin [mi] |
periplogenin 3-o-(.beta.-d-glucopyranosyl-(1->4)-.beta.-d-cymaropyranoside) |
AS-75113 |
(3?,5?)-3-[(2,6-dideoxy-4-o-?-d-glucopyranosyl-3-o-methyl-?-d-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-card-20(22)-enolide; periplocin (6ci,7ci,8ci); (3?,5?)-3-[(2,6-dideoxy-4-o-?-d-glucopyranosyl-3-o-methyl-?-d-ribo-hexopyranosyl)oxy]-5,14-dihydroxycard-20 |
AKOS030573522 |
3-[(3s,5s,8r,9s,10r,13r,14s,17r)-5,14-dihydroxy-3-[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] |
card-20(22)-enolide, 3-[(2,6-dideoxy-4-o-beta-d-glucopyranosyl-3-o-methyl-beta-d-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-, (3beta,5beta)- |
CS-0016801 |
HY-N1381 |
CCG-270383 |
Q27252090 |
DTXSID501030586 |
Piplocin is a cardiac glycoside and has been used widely in the clinic for its cardiotonic, anti-inflammatory and anti-tumor effects. It shows poor absorption when administered orally.
Periplocin could increase cell viability to a level lower than ouabain in the MTT analysis, but decrease LDH release simultaneously.
Excerpt | Reference | Relevance |
---|---|---|
"Periplocin displays a promising mechanism of action in sarcoma cells because altering the death receptor expression is an interesting target in sarcoma treatment especially to overcome TRAIL resistance." | ( Periplocin, the most anti-proliferative constituent of Periploca sepium, specifically kills liposarcoma cells by death receptor mediated apoptosis. Bauer, R; Kaltenegger, H; Kretschmer, N; Kunert, O; Leithner, A; Lohberger, B; Rinner, B; Stuendl, N; Wagner, S; Wohlmuther, J, 2018) | 3.37 |
"Periplocin could increase cell viability to a level lower than ouabain in the MTT analysis, but decrease LDH release simultaneously. " | ( Gene expression profiling of the proliferative effect of periplocin on mouse cardiac microvascular endothelial cells. Gao, XM; Hu, LM; Jiang, M; Liu, H; Liu, Y; Wang, XY; Zhang, BL; Zhang, H, 2010) | 2.05 |
Excerpt | Reference | Relevance |
---|---|---|
"Periplocin is used for treatment of rheumatoid arthritis, reinforcement of bones and tendons, palpitations or shortness of breath and lower extremity edema in traditional medicine. " | ( Comparative proteomic analysis of anti-cancer mechanism by periplocin treatment in lung cancer cells. Kang, J; Lu, Z; Song, Q; Yang, J; Yang, P; Zhang, X; Zhao, X, 2014) | 2.09 |
Excerpt | Reference | Relevance |
---|---|---|
" Orally ingesting periplocin in high doses or over prolonged periods would cause serious adverse reactions, especially cardiotoxicity, which limits the applications of periplocin in clinical therapy." | ( Metabolomics study on the periplocin-induced cardiotoxicity and the compatibility of periplocin and Panax notoginseng saponins in reducing cardiotoxicity in rats by GC-MS. Fan, Y; He, J; Huang, X; Li, L; Ouyang, H; Wang, S; Wang, W; Xue, Z, 2021) | 1.26 |
The proposed method was successfully applied to evaluating the pharmacokinetic studies of periplocin and its metabolites in rats. Using this method, the concentrations were established after oral administration of Cortex Periplocae extract to rats.
Excerpt | Reference | Relevance |
---|---|---|
" No obvious indications of metabolism were observed in the in vitro incubation system, which suggests that periplocin did not interact with the hepatic drug metabolic enzymes." | ( P-glycoprotein- and organic anion-transporting polypeptide-mediated transport of periplocin may lead to drug-herb/drug-drug interactions. Deng, F; He, X; Koomson, E; Liang, S; Martey, ON; Shi, X; Wen, H; Xing, H, 2014) | 0.84 |
Excerpt | Reference | Relevance |
---|---|---|
" The efflux function of P-gp may be partly responsible for the low permeability and bioavailability of periplocin." | ( P-glycoprotein- and organic anion-transporting polypeptide-mediated transport of periplocin may lead to drug-herb/drug-drug interactions. Deng, F; He, X; Koomson, E; Liang, S; Martey, ON; Shi, X; Wen, H; Xing, H, 2014) | 0.84 |
Excerpt | Relevance | Reference |
---|---|---|
" In this study, a sensitive and reliable liquid chromatography-tandem mass spectrometry method was developed and validated to identify and quantify periplocin and its two metabolites in rat tissue after a single dosage of perplocin at 50 mg/kg." | ( Tissue distribution study of periplocin and its two metabolites in rats by a validated LC-MS/MS method. Azietaku, JT; Chang, Y; Gao, X; He, J; Liu, H; Ouyang, H; Sun, M; Tang, Z; Wang, M; Zhang, D, 2018) | 0.97 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (8.57) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (14.29) | 29.6817 |
2010's | 17 (48.57) | 24.3611 |
2020's | 10 (28.57) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.70) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 36 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |